Detailed price information for Nervgen Pharma Corp (NGEN-X) from The Globe and Mail including charting and trades.

Spinal cord interface and stimulation surgeries are offering new hope to paralysed patients by restoring movement via digital neural bridges.

Research Capital analyst André Uddin has maintained his “Speculative Buy” rating and $7.70 target price on NervGen Pharma ...

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by differences in communication, behavior and ...

More than £3,000 was raised as Sikhs walked through Coventry to help those affected by Motor Neurone Disease (MND).

The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...

Scientists have identified a new drug that safeguards nerve cells harmed by 'one of the cruellest diseases', providing hope for substantially slowing its progress. Preliminary studies with M102 showed ...

Nearly 8% of the general population experiences sleep paralysis, but people are unaware that REM sleep disruptions can create ...

A New York-based biotech firm announced it has raised an additional $200 million in financing to advance commercialization of ...

A drug candidate found to protect nerve cells damaged by motor neuron disease (MND), could offer new hope to people living ...

One of the most important functions of interneurons in the knee-jerk reflex is to mediate reciprocal inhibition. This process ensures that the contraction of the quadriceps muscle is accompanied by ...